CAMBRIDGE, Mass. (December 24, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today congratulates InVivo Therapeutics’ sponsored athlete Jason Fowler on winning the 2012 Ironman 70.3 World Triathlon Championships in Las Vegas, NV.
As a nationally ranked amateur motocross racer, Fowler was paralyzed from the chest down at the age of 17 as the result of a motorcycle accident. Following his accident Fowler remained an avid athlete, and has since completed 150 road races, 30 marathons, and 29 triathlons, and has won several local and national competitions including two World Championships. He also regularly volunteers his time to traumatically injured children and trains aspiring athletes.
Most recently, Fowler took first place in the 2012 Ironman 70.3 World Triathlon Championships in Las Vegas, NV. As a triathlete, Fowler competes conventionally in the swim and participates in the bike ride stage using a handcycle, and in the run portion using a racing wheelchair. Remarkably, the entire distance of the race is covered using only the strength and endurance of the upper body.
“Jason’s commitment to his sport is only exceeded by his commitment to the spinal cord injury community,” said Frank Reynolds, InVivo Chief Executive Officer. “We all know the importance of first responders at any emergency, but well after the doctors, nurses, and rehabilitation experts finish their work, Jason and his team at the Boston Chapter of the National Spinal Cord Injury Association arrive to teach patients how to adjust and adapt to a new set of possibilities for their lives. Jason is a Ironnman in every sense of the word.”
To read more and see a great video about Jason, please visit: www.jasonfowlerracing.com and http://boston.cbslocal.com/2012/12/05/paraplegic-athlete-from-belmont-crowned-iron-man-champion-of-world/.
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and acts as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device designation and is currently being studied in a pilot study for the treatment of complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and include statements regarding the enrollment of additional patients in the scaffold pilot study following the reopening of enrollment and its ability to conduct a second pivotal study. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as amended, and its other filings with the SEC, including the Company’s Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.